<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696525</url>
  </required_header>
  <id_info>
    <org_study_id>PTHO1601</org_study_id>
    <nct_id>NCT02696525</nct_id>
  </id_info>
  <brief_title>Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients</brief_title>
  <official_title>A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Valley Biotechnology Incorporated</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conduct a prospective study to confirm blood and urine ctDNA detection value in
      non-small-cell lung cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown the feasibility of detecting mutation status by blood and urine
      circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no
      prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC
      patients.

      We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in
      surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC
      patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Lead time of tumor relapse detection by blood or urine circulation tumor DNA than radiographic approaches</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lead time of tumor relapse detection by blood or urine circulation tumor DNA than tumor markers</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concordance of ctDNA genomic alterations detection in peripheral blood and urine with those in matched tumor sample</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of blood and urine ctDNA concentration before surgery with clinical features and prognosis</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of blood and urine ctDNA concentration 3 days after surgery with clinical features and prognosis</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CtDNA predictive value between locoregional recurrence and distant metastasis</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Carcinoma</condition>
  <condition>Non-small-cell Lung Cancer</condition>
  <condition>Lung Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh tumor tissue, urine samples and blood samples were collected from each patient.

      Time:Preoperative, 3 days and 3、6、12、18、24、30、36 months after surgery.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically confirmed stage ⅢA non-small cell lung cancer patients who have the same
        driver mutation in tumor tissue and circulating tumor DNA(blood or urine)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 80 years

          -  Undergo radical surgery（R0 resection）

          -  Histologically confirmed diagnosis of stage ⅢA non-small cell lung cancer

          -  Positive Driver mutation(EGFR、PTEN、PIK3CA、BRAF、K-RAS、Her2) in tumor tissue

          -  Blood or urine circulating tumor detect the driver mutation detected in tumor tissue

          -  Patients must have given written informed consent

        Exclusion Criteria:

          -  Unable to comply with the study procedure

          -  Malignant tumor history within the past 5 years

          -  Patients who received any treatment prior to resection

          -  R1 or R2 resection

          -  Coexisting small cell lung cancer

          -  Received target drug therapy after surgery

          -  Unqualified blood or urine samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yilong Wu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Guang Dong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Xu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Jiang Su Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kezhong Chen, M.D.</last_name>
    <phone>（+86）13488752289</phone>
    <email>mdkzchen@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lixin Zhou, M.D.</last_name>
    <phone>（+86）13811264336</phone>
    <email>zhoulixin04@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kezhong Chen, M.D.</last_name>
      <phone>+8613488752289</phone>
      <email>mdkzchen@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lixin Zhou, M.D.</last_name>
      <phone>+8613811264336</phone>
      <email>zhoulixin04@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fan Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kezhong Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lixin Zhou, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guang Dong General Hospital, Thoracic Surgery</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuening Yang, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Wenzhao Zhong, M.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Yilong Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xuening Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenzhao Zhong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiang Su Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Yin, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Lin Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Yin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Jun Wang</investigator_full_name>
    <investigator_title>Chief，Thoracic Surgery Service</investigator_title>
  </responsible_party>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>lead time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

